IE67294B1 - Process for the preparation of 2-acylamino-9-acyl-6-halopurine - Google Patents

Process for the preparation of 2-acylamino-9-acyl-6-halopurine

Info

Publication number
IE67294B1
IE67294B1 IE451790A IE451790A IE67294B1 IE 67294 B1 IE67294 B1 IE 67294B1 IE 451790 A IE451790 A IE 451790A IE 451790 A IE451790 A IE 451790A IE 67294 B1 IE67294 B1 IE 67294B1
Authority
IE
Ireland
Prior art keywords
compound
formula
preparation
acyl
pyridine
Prior art date
Application number
IE451790A
Other versions
IE904517A1 (en
Inventor
Winfried Hertzsch
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IE904517A1 publication Critical patent/IE904517A1/en
Publication of IE67294B1 publication Critical patent/IE67294B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

2-Acylamino-9-acyl-6-halogeno-purine can be prepared by acylating 2-acylamino-6-halogeno-purine in the presence of a catalyst without the contaminating production of 2-diacylamino-9-acyl-6-chloro-purine.

Description

2-Acyl amino-9-acyl-6 -chloropurines are very widely utilizable intermediates in the pharmaceutical industry for nucleoside syntheses.
The preparation of 2-acetamido-9-acetyl-6-chloropurine by acetylation of 2-amino-6-chloropurine has already been described (Synthetic Procedures in Nucleic Acid Chemistry, Vol. 1, 1968, W.W. Zorbach and R.S. Tipson Ed., John Wiley & Sons, New York, 25 - 27) . In this case, the acetylation in position 9 of the purine ring is preferably carried out under reflux conditions. However, even after 5 to 10 minutes reaction time, 2-diacetamido9-acetyl-6-chloropurine is also formed as an impurity in addition to 2-acetamido-9-acetyl-6-chloropurine. The total yield of the two compounds is 75%.
Some experiments moreover show that under the abovemen tioned conditions at reflux temperatures of 135C to 140°C, not only are larger amounts of 2-diacetamido-9acetyl-6-chloropurine formed, but a replacement of chlorine by oxygen in position 6 of the purine ring additionally also takes place. These disadvantages particularly have an influence in the preparation of larger amounts of 2 -acetamido- 9 -acetyl- 6 - chloropur ine. On the production scale, longer heating and cooling times cannot be avoided, so that the high thermal loadings lead to strongly contaminated 2-acetamido-9-acetyl-6-chloropurine batches.
Surprisingly, it has now been found that by the use of a catalyst the purity of 2-acylamino-9-acyl-6-halopurine can be substantially improved in the preparation from 2acylamino- 6 -halopurine.
The invention thus relates to a process for the preparation of the compound of the formula I in which R1 and R2, which can be identical or different, are a straight-chain or branched alkanoyl group having 2 to 10 carbon atoms or an aralkanoyl group having 7 to 10 carbon atoms and X is fluorine, chlorine, bromine or iodine, by acylation of the compound of the formula II IX in which R1 and X have the abovementioned meaning, which comprises using pyridine or a pyridine derivative as the catalyst and carrying out the acylation at a temperature of between 10°C and 90°C.
The invention will now be described in detail in the following, in particular in its preferred embodiments.
The expression alkanoyl group having 2 to 10 carbon atoms is to be understood as meaning, for example, the radicals of the following acids: acetic acid, propionic acid, n-butyric acid, i-butyric acid, n-valeric acid, i-valeric acid, methylethylacetic acid, trimethylacetic acid, caproic acid, caprylic acid, capric acid, heptanoic acid and nonanoic acid. The expression aralkanoyl group having 7 to 10 carbon atoms means, for exasple, the radicals of the following compounds: benzoic acid, phenylacetic acid, phenylpropanoic acid, phenyl-n-butyric acid or phenyl-i-butyric acid.
The reaction, according to the invention, of 2-acylamino6-halopurine to give 2-acylamino-9-acyl-6-halopurine is carried out in the presence of an acylating agent, with V the aid of which the amino group in the 9-position of the compound of the formula IX can be substituted by a straight-chain or branched alkanoyl group having 2 to 10 carbon atoms or an aralkanoyl group having 7 to 10 carbon atoms. Acylating agents which can be used are carboxylic anhydrides, such as, for example, acetic anhydride, propionic anhydride, butyric anhydride, valeric anhydride, caprylic anhydride, capric anhydride or caproic anhydride. However, mixed anhydrides can also be employed. In addition, acylating agents which can also be used are carboxylic acid halides, such as acetyl chloride, propionyl chloride, phenylacetyl chloride, phenylbutanoyl chloride, benzoyl chloride, acetyl bromide, or propionyl bromide. The acylating agents can be dissolved in an inert solvent beforehand. Inert solvents which can be used are compounds such as, for example, dimethylacetamide, toluene, benzene or N-methylpyrrolidone.
-Acylamino-6-halopurine is mixed with the acylating agent and heated with the addition of a catalyst. The following compounds can be used as catalyst: pyridine, pyridine derivatives such as, for example, 4dimethylaminopyridine, 4- (4-methyl-1-piperidinyl)pyridine, 4-pyrrolidinopyridine, 4-morpholinopyridine or N-methylimidazole. Preferably, 4-dimethylaminopyridine is used. 'i The molar ratio of 2-acyl amino-6-halopurine to the acylating agent can be varied within a range from 1:1 to 1:40. The reaction is preferably carried out in a range from 1:5 to 1:30. The molar ratio of catalyst to 2acylamino-6-halopurine can vary within a range from 1:5 to 1:100. Preferably, a molar ratio of 1:35 to 1:80 is maintained.
The reaction temperature is between 10°C and 90°C, in particular between 20°C and 70°C. The reaction time is between 0.5 and 7 hours, in particular between 1 and 3 hours. The course of the reaction is determined by sample removal and quantitative analysis of the final product with the aid of known titration methods. After this, the mixture is stirred at temperatures between 0°C and 10°C for a. further 0.5 to 2 hours. After filtration, the compound of the formula I is obtained in high purity.
The sequence of the individual process steps can also be varied. A person skilled in the art does not find it difficult to find the optimum sequence for the reaction process.
The preparation of 2-acylamino-6-halopurines is carried out in a manner known per se by halogenation and acylation of purines (EP 0,203,685; D.J. Brown, Heterocyclic Compounds, 135-197, 1971; Bowles W.A. et al., J. Med. Chem., 471-480, 6, 1963).
In comparison to the route known hitherto for the preparation of 2-acylamino-9-acyl-6-halopurines, the process according to the invention opens up the advantage of obtaining the final product in high purity and yield. The catalysts used catalyze the acylation in position 9 of the purine ring, but not the formation of 2-diacylamino-9-acyl-6-halopurines. All process steps which are needed for the separation of the 2-diacylamino-9-acyl-6halopurine derivatives thus become unnecessary.
The example shown below is used to illustrate the invention further.
Example: 1.1 kg (5.2 mol) o£ 2-acetamido-6-chloropurine are suspended in 11 1 of acetic anhydride and 87.0 g (0.71 mol) of 4-dime thyl aminopyridine are added. The mixture is stirred at 50°C for two hours, then cooled and stirred at 0°C to 5°C for half an hour. The product is filtered off, washed with diisopropyl ether and dried in vacuo at 50°C. 1.16 kg of 2-acetamido-9-acetyl-6-chloropurine are obtained.
Yield: 88% of theory Purity: 99.1% (titration) ^H-NMR (in DMSO) : δ (ppm): 2.25 N-C-CH3 2.93 9-COCH3 8.93 8-H 11.06 HN-CO-C

Claims (8)

1. Patent claims:
1. A process for the preparation of the compound of the formula I X in which R 1 and R 2 , which can be identical or 5 different, are a straight-chain or branched alkanoyl group having 2 to 10 carbon atoms or an aralkanoyl group having 7 to 10 carbon atoms and X is fluorine, chlorine, bromine or iodine, by acylation of the compound of the formula IZ 10 in which R 1 and X have the abovementioned meaning, which conqprises using pyridine or a pyridine derivative as the catalyst and carrying out the acylation at a temperature of between 10°C and 90°C. ; t 2. The process as claimed in claim 1, wherein carboxylic anhydride or carboxylic acid halide are used as the acylating agent. The process as claimed in claim 1, wherein
2. 4-dimethylaminopyridine, 4- (4-methyl-1-piper idinyl) 3. pyridine, 4-pyrrolidinopyridine, 4-morpholinopyridine or N-methylimidazole are used as the pyridine derivative. 4. The process as claimed in one or more of claims 1 to
3. 5 3, wherein the molar ratio of the compound of the formula II to acylating agent is in the range from 1:1 to 1:40. 5. The process as claimed in claim 4, wherein the molar ratio is in the range from 1:5 to 1:30. 10
4. 6. The process as claimed in one or more of claims 1 to 5, wherein the molar ratio of catalyst to the compound of the formula II is in the range from 1:5 to 1:100.
5. 7. The process as claimed in claim 6, wherein the molar 15 ratio is between 1:35 to 1:80.
6. 8. The process as claimed in claim 1, wherein the reaction temperature is between 20°C and 70°C.
7. 9. A process according to claim 1 for the preparation of a compound of the formula I given and defined 2 θ therein, substantially as hereinbefore described and exemplified.
8. 10. A compound of the formula I given and defined in claim 1, whenever prepared by a process claimed in a preceding claim.
IE451790A 1989-12-16 1990-12-14 Process for the preparation of 2-acylamino-9-acyl-6-halopurine IE67294B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3941658A DE3941658A1 (en) 1989-12-16 1989-12-16 METHOD FOR PRODUCING 2-ACYLAMINO-9-ACYL-6-HALOGEN PURIN

Publications (2)

Publication Number Publication Date
IE904517A1 IE904517A1 (en) 1991-06-19
IE67294B1 true IE67294B1 (en) 1996-03-20

Family

ID=6395643

Family Applications (1)

Application Number Title Priority Date Filing Date
IE451790A IE67294B1 (en) 1989-12-16 1990-12-14 Process for the preparation of 2-acylamino-9-acyl-6-halopurine

Country Status (8)

Country Link
EP (1) EP0433845B1 (en)
JP (1) JPH0692965A (en)
AT (1) ATE120748T1 (en)
DE (2) DE3941658A1 (en)
DK (1) DK0433845T3 (en)
ES (1) ES2071731T3 (en)
IE (1) IE67294B1 (en)
PT (1) PT96179B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201961D0 (en) * 1992-01-30 1992-03-18 Smithkline Beecham Plc Pharmaceuticals
JPH07133276A (en) * 1993-09-17 1995-05-23 Jiyuuzen Kagaku Kk Production of 2-acetylamono-6-chloropurine
EP1375502B1 (en) 2001-04-05 2007-06-13 Sumitomo Chemical Company, Limited Process for producing 2,6-dihalogenopurine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW22283A1 (en) * 1982-10-14 1985-05-22 Wellcome Found Antiviral compounds
EP0138683A3 (en) * 1983-09-30 1988-01-20 Merck & Co. Inc. Purine derivatives, their application in anti-viral compositions

Also Published As

Publication number Publication date
ES2071731T3 (en) 1995-07-01
EP0433845B1 (en) 1995-04-05
ATE120748T1 (en) 1995-04-15
IE904517A1 (en) 1991-06-19
EP0433845A1 (en) 1991-06-26
DE59008852D1 (en) 1995-05-11
DE3941658A1 (en) 1991-06-20
DK0433845T3 (en) 1995-07-31
JPH0692965A (en) 1994-04-05
PT96179B (en) 1998-04-30
PT96179A (en) 1991-09-30

Similar Documents

Publication Publication Date Title
US3029291A (en) Method for making alkylidenebis
EP0704445B1 (en) Preparation of N-9 substituted guanine compounds
IE67294B1 (en) Process for the preparation of 2-acylamino-9-acyl-6-halopurine
HU193589B (en) Process for preparing fluorinated phtaloyl- and terephtaloyl compounds
EP1551839B1 (en) Process for preparing 9-¬4-acetoxy-3-(acetoxymethyl)but-1-yl -2-aminopurine
KR101150627B1 (en) Process for the preparation of n-alkyl-2(hydroxy-4 benzoyl)-3 benzofurans and its intermediates thereof
US4617395A (en) Preparation of quinolines
US3152148A (en) Preparation of comenic and pyromeconic acids
JP2019507156A (en) Process for producing 4-alkoxy-3-hydroxypicolinic acid
US5434263A (en) Process for the preparation of 2-acylamino-6-halopurine from 2,9-diacylguanine
JPH0597840A (en) Production of 3-acylamino-6-phenyloxy-7-alkyl sulfonylamino-4h-1-benzopyran-4-one or its salt
EP0206789B1 (en) Crystalline hydroxyphenylpropionic acid ester and its production
JPS6035347B2 (en) Synthesis method of α-tocopherol
KR940000062B1 (en) Process for preparation of acylcyanide in medium anhydride
US6114525A (en) Method for purifying nucleic acid derivatives
CA1171081A (en) Production of purine derivatives and intermediates therefor
EP0111299B1 (en) Fluorine-containing uridine derivative and preparation and use thereof
JP3160439B2 (en) Method for producing acetylguanine
US6043364A (en) Regiospecific process for synthesis of acyclic nucleosides
CN113045491B (en) Preparation method of lenvatinib and intermediate
CA2207464A1 (en) Crystal of n-{(quinolin-2-yl)phenylsulfonamides and process for producing the same
EP0193973A1 (en) Method of preparation of 2-alkylpyrimidine by dehydrogenation of 2-alkyltetrahydropyrimidine
US5371224A (en) Process for preparing 2,5-dibromopyrimidine
JP3114244B2 (en) Sorbitol derivative
US4935534A (en) 1-(N-formylamino)-2,4-dicyanobutane and a process for its production

Legal Events

Date Code Title Description
MM4A Patent lapsed